Viral Vector & Plasmid DNA Manufacturing Market to Hit $ 2,247.7 Million, Globally, by 2027 at 22.1% CAGR: The Insight Partners

 Breaking News
  • No posts were found

Viral Vector & Plasmid DNA Manufacturing Market to Hit $ 2,247.7 Million, Globally, by 2027 at 22.1% CAGR: The Insight Partners

November 24
21:53 2021
The viral vector & plasmid DNA manufacturing market is expected to grow owing to factors such as growing awareness of gene therapy and increasing prevalence of genetic disorders and infectious diseases across the world. Additionally, growth of the global healthcare market is likely to have a positive impact on the market in the coming years.

According to The Insight Partners market research study of ‘Viral Vector & Plasmid DNA Manufacturing Market to 2027 – Global Analysis and Forecast by Product, and Application,’ the global Viral Vector & Plasmid DNA Manufacturing market is expected to reach US$ 2,247.7million by 2027 from US$ 459.4million in 2019. The market is estimated to grow at a CAGR of 22.1% from 2020 to 2027. The report highlights trends prevailing in the global viral vector & plasmid DNA manufacturing market and the factors driving market along with those that act as hindrances.

Strategic Insights:

Report Coverage             

(Details)

Market Size Value in      

(US$ 459.4million in 2019)

Market Size Value by    

(US$ 2,247.7 million by2027)

Growth Rate     

(CAGR of 22.1% from 2020 to 2027)

Forecast Period

(2020- 2027)

Base Year           

(2020)

No. of Pages     

(140)

No. Tables          

(45)

Segments covered         

(By Product, Application, and Geography)

Regional scope 

(North America; Europe; Asia Pacific; Latin America; MEA)

Country scope  

(US, UK, Canada, Germany, France, Italy, Australia, Russia, China, Japan, South Korea, Saudi Arabia, Brazil, Argentina)

Report coverage             

(Revenue forecast, company ranking, competitive landscape, growth factors, and trends)

Get Sample PDF Copy of Viral Vector & Plasmid DNA Manufacturing Market at: https://www.theinsightpartners.com/sample/TIPRE00003074/

Gene delivery into target cells can be performed using several different vectors. These are broadly classified into viral and non-viral vectors, both of which present benefits and risks. Viral vectors are tools that are commonly used by molecular biologists to deliver genetic material into cells. The non-viral vectors are naked DNA, particle-based, and chemical-based. Driving factors such as growing awareness of gene therapy, increasing prevalence of genetic disorders, and infectious diseases across the world are expected to upsurge the market growth.

Increasing Prevalence of Genetic Disorders and Infectious Diseases

According to a study published by National Hemophilia Foundation in 2015, an estimated 400,000 people across the globe are suffering from hemophilia. Further, according to a study published by the NIH in 2019, sickle cell anemia affects an estimated 100,000 people in the US. The application of gene therapy for the treatment of viral infections such as herpes simplex viruses, adeno-associated viruses, poxviruses, and retroviruses is expected to drive the adoption of gene therapies as one of the prominent treatment alternatives, which will eventually boost the growth of the viral vectors and plasmid DNA manufacturing market during the forecast period.

Gene therapies with the help of viral vectors are widely recommended for a range of monogenic disorders, such as sickle cell anemia, severe combined immunodeficiency, cystic fibrosis, hemophilia, Duchenne muscular dystrophy, Parkinson’s disease, and Gaucher disease. For instance, in October 2019, a group of researchers at the National Institutes of Health (NIH) developed a new improved viral vector for the treatment of sickle cell anemia. According to the researchers, the new vector is 10 times efficient than already existing viral vectors in the market.

COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns.

Download the Latest COVID-19 Analysis on Viral Vector & Plasmid DNA Manufacturing Market Growth Research Report at: https://www.theinsightpartners.com/covid-analysis-sample/TIPRE00003074

Based on product, the viral vector & plasmid DNA manufacturing market is segmented into viral vectors and non-viral vectors. The viral vectors segment held the larger share of the market in 2019, owing to the factor that these are used in basic research, gene therapy, and vaccine preparation. Moreover, they can be of different types such as retroviruses, lentiviruses, adenoviruses, adeno-associated viruses, and hybrids. Additionally, effective gene delivery, high transfection efficiency, and stable gene expression have made viral vectors a preferred choice for gene transfer. Hence the growing demand is likely to propel the growth of the market at a highest CAGR during the forecast period.

Based on end user, the viral vector & plasmid DNA manufacturing market is segmented into cancer, inherited disorders, viral infections, and others. The cancer segment held the largest share of the market in 2019 and the same segment is estimated to register the highest CAGR in the market during the forecast period. The growing prevalence of cancer is likely to grow market at a faster CAGR.

Viral Vector & Plasmid DNA Manufacturing Market: Competitive Landscape and Key Developments

Brammer Bio, Sanofi, Cardinal Health Inc., FUJIFILM Diosynth Biotechnologies, Cell and Gene Therapy Catapult, Cobra Biologics, FinVector, Kaneka Eurogentec S.A., MassBiologics, Spark Therapeutics, and Uniqure are among the leading companies operating in the viral vector & plasmid DNA manufacturing market.

Order a Copy of Viral Vector & Plasmid DNA Manufacturing Market Shares, Strategies and Forecasts 2021-2027 Research Report at: https://www.theinsightpartners.com/buy/TIPRE00003074/

Browse Related Reports and get Sample copy

Refurbished DNA Sequencing Platforms Market Forecast to 2028 – Covid-19 Impact and Global Analysis – By Application (Plant Biotechnology, Biomarker Discovery, Forensics, Personalized Medicines, Oncology Study, Metagenomics, Epigenomics); End-User (Biotechnology and Pharmaceutical Companies, Research Laboratories, Academic Institutes, Hospitals and Clinics) and Geography

 

https://www.theinsightpartners.com/sample/TIPRE00009655/

DNA Next Generation Sequencing Market to 2025 – Global Analysis and Forecasts By Product (Platforms, Services and Consumables); Application (Diagnostics, Drug Discovery, Precision Medicine, & Other Applications); & End User (Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Hospitals Clinics, & Other End Users) and Geography

https://www.theinsightpartners.com/sample/TIPRE00002934/

About Us:

 

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Research Study – https://liverpoolstudentmedia.com/author/theinsightpartners/ 

Gene delivery into target cells can be performed using several different vectors. These are broadly classified into viral and non-viral vectors, both of which present benefits and risks. Viral vectors are tools that are commonly used by molecular biologists to deliver genetic material into cells. The non-viral vectors are naked DNA, particle-based, and chemical-based. Driving factors such as growing awareness of gene therapy, increasing prevalence of genetic disorders, and infectious diseases across the world are expected to upsurge the market growth.

Media Contact
Company Name: The Insight Partners
Contact Person: Sameer Joshi
Email: Send Email
Phone: +1-646-491-9876
City: Pune
State: Maharashtra
Country: India
Website: https://www.theinsightpartners.com/pr/viral-vector-and-plasmid-dna-manufacturing-market

Categories